Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-03T03:11:08.281Z Has data issue: false hasContentIssue false
  • English
  • Français

The role of calcium channel blockers in the treatment of women with preeclampsia

Part of: Bespoke shallow archive Weizmann

Published online by Cambridge University Press:  15 January 2010

R Lewis ,
M Belfort  and
B Sibai
R Lewis
Affiliation:
Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of Tennessee, Memphis, Tennessee.
M Belfort
Affiliation:
Department of Obstetrics & Gynecology and Anesthesiology, Division of Maternal Fetal Medicine, Baylor College of Medicine, Houston, Texas.
B Sibai*
Affiliation:
Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of Tennessee, Memphis, Tennessee.
*
Baha Sibai, MD, Department of Obstetrics and Gynecology, 853 Jefferson Ave., Rm E-102, Department of Obstetrics and Gynecology, University of Tennessee, Memphis 38103.
Get access Rights & Permissions [Opens in a new window]

Extract

Preeclampsia was originally known as a process whereby an unknown “toxin” was responsible for a variety of responses. While this toxin has yet to be determined, many theories have prevailed as to the appropriate therapy for this condition.

Recently, antihypertensive therapy has become increasingly regarded as an important component of the medical management of women with preeclampsia. Initially, the ideal therapy for peripartum acute hypertensive emergencies was felt to be a smooth muscle relaxant and the most commonly prescribed agent was hydralazine. This drug was felt to be beneficial because of its action on vascular smooth muscle, decreasing vasospasm. Outside of the United States diazoxide was also used for this purpose, although this drug has been replaced because of the high incidence of fetal distress. Another agent that was frequently used was α-methyldopa which was initially considered to be the treatment of choice in the treatment of patieats with moderate and severe preeclampsia. Recently, α-methyldopa has been reserved for the outpatient management of gestational hypertension, especially in women with mild preeclampsia or chronic hypertension.

Type
Research Article
Information
Fetal and Maternal Medicine Review , Volume 8 , Issue 1 , February 1996 , pp. 19 - 27
Copyright
Copyright © Cambridge University Press 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Redman, CWG. Treatment of hypertension in pregnancy. Kidney Int 1980; 18: 267–78.CrossRefGoogle ScholarPubMed
2Kelly, JV. Drugs used in the management of toxemia of pregnancy. Clin Obstet Gynecol 1977; 20: 395–410.CrossRefGoogle ScholarPubMed
3Barden, TP, Keenan, WJ. Effects of diazoxide in human labor and the fetus-neonate. Obstet Gynecol 1971; 37: 631–32.Google Scholar
4Leather, HM, Humphreys, DM, Baker, P, Chadd, MA. A controlled trial of hypotensive agents in hypertension in pregnancy. Lancet 1968; 2: 488–90.CrossRefGoogle ScholarPubMed
5Redman, CWG, Beilin, LJ, Bonnar, J. Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects. Br J Obstet Gynaecol 1977; 84: 419–26.CrossRefGoogle ScholarPubMed
6Rubin, PC, Butters, L, Clark, DM, Reynolds, B, Sumner, DJ, Steedman, D et al. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet 1983; 1: 431–34.Google ScholarPubMed
7Pickles, CJC, Symonds, EM, Broughton Pipkin, F.The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br J Obstet Gynaecol 1989; 96: 38–43.CrossRefGoogle Scholar
8Brown, MA, Whitworth, JA. Hypertension in pregnancy. In: Stein, JH, Bennett, WM, McCarron, DA. Pharmacology and management of hypertension. New York, NY: Churchill Livingstone Inc. 1994; 89–116.Google Scholar
9Walters, BNJ, Redman, CWG. Treatment of severe pregnancy-associated hypertension with the calcium antagonist nifedipine. Br J Obstet Gynaecol 1984; 91: 330–36.CrossRefGoogle ScholarPubMed
10Pederson, OL, Mikkelsen, E. Acute and chronic effects of nifedipine in arterial hypertension. Eur J Clin Pharmacol 1978; 14: 375–81.CrossRefGoogle Scholar
11Guazzi, MD, Fiorentini, C, Olivari, MT, Bartorelli, A, Necchi, G, Polese, A. Short- and long-term efficacy of a calcium-antagonist agent (nifedipine) combined with methyldopa in the treatment of severe hypertension. Circulation 1980; 61: 913–19.CrossRefGoogle Scholar
12Antman, E, Muller, J, Goldberg, S, MacAlpin, R, Rubenfire, M, Tabatznik, B et al. Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. New Engl J Med 1980; 302: 1269–73.CrossRefGoogle ScholarPubMed
13Manninen, A, Metsa-Ketela, T, Tuimala, R, Vapaatalo, H. Nifedipine increases urinary excretion of prostacyclin metabolite in hypertensive pregnancy. Pharmacol Toxicol 1991; 69: 60–63.CrossRefGoogle ScholarPubMed
14Skajaa, K, Svane, D, Andersson, K, Forman, A. Effects of magnesium and isradipine on contractile activation induced by the thromboxane A2 analog U46619 in human uteroplacental arteries in term pregnancy. Am J Obstet Gynecol 1990; 163: 1323–33.CrossRefGoogle ScholarPubMed
15Wide-Swensson, D, Ingemarsson, I, Andersson, K-E, Anandakumaran, C, Arulkumaran, S et al. Isradipine reduces blood pressure, but not placental blood flow in pregnancy induced hypertension. Clin Exp Hyperten Pregnancy 1991; BIO: 49–60.CrossRefGoogle Scholar
16Singh, BN. The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol 1986; 21: 109S–21S.CrossRefGoogle ScholarPubMed
17Fleckenstein, A. Calcium antagonism in heart and smooth muscle: experimental facts and therapeutic prospects. New York: Wiley & Sons, 1983.Google Scholar
18Spedding, M, Paoletti, R. Classification of calcium channels and the site of action of drugs modifying channel function Pharmacol Rev 1992; 44: 363–76.Google Scholar
19Murad, F. Drugs used for the treatment of angina: organic nitrates, calcium channel blockers, and ß-adrenergic antagonists. In: Gilman, AG, Rail, TW, Nies, AS, Taylor, P (eds). The pharmacological basis of therapeutics. 8th edition, Volume 1 Singapore: McGraw-Hill International Editions, 1992: 764–83.Google Scholar
20Andersson, K-E, Ingemarsson, I, Umsten, U, Wingerup, L. Inhibition of prostaglandin-induced uterine activity by nifedipine. Br, J Obstet Gynaecol 1979; 86: 175–59.CrossRefGoogle ScholarPubMed
21Vanhoutte, PM. The expert committee of the World Health Organization on classification of calcium antagonists: the viewpoint of the rapporteur. Am J Cardiol 1987; 59: 3A–8A.CrossRefGoogle Scholar
22Allen, J, Maigaard, S, Forman, A, Jacobsen, P, Jespersen, LT, Hansen, KPB et al. Acute effects of nitrendipine in pregnancy-induced hypertension. Br J Obstet Gynaecol 1987; 94: 222–26.CrossRefGoogle ScholarPubMed
23Belfort, MA, Moore, PJ. Verapamil in the treatment of severe postpartum hypertension. S Afr Med J 1988; 74: 265–67.Google ScholarPubMed
24Wide-Swensson, K, Ingemarsson, I, Arulkumaran, S, Andersson, K-E. Effects or isradipine, a new calcium antagonist, on maternal cardiovascular system and uterine activity in labour. Br J Obstet Gynaecol 1990; 97: 945–49.CrossRefGoogle ScholarPubMed
25Ingemarsson, I, Wide-Swensson, D, Andersson, K-E, Arulkumaran, S. Maternal and fetal cardiovascular changes after intravenous injections of isradipine to pregnant women. Drugs 1990; 40: 58–59.CrossRefGoogle ScholarPubMed
26Saragoça, MA, Mulinali, RA, Oliviera, AF, Portela, J, Plavnik, FL, Melegari, D et al. Parenteral isradipine reduces blood pressure in hypertensive crisis. Am J Hypertens 1993; 6: 112S–114S.CrossRefGoogle ScholarPubMed
27Belfort, MA, Anthony, J, Buccimazza, A, Davey, DA. Hemodynamic changes associated with intravenous infusion of the calcium antagonist verapamil in the treatment of severe gestational proteinuric hypertension. Obstet Gynecol 1990; 75: 970–74.Google ScholarPubMed
28Belfort, MA, Kirshon, B. Nisoldipine - a new orally administered calcium antagonist used in the treatment of severe postpartum pregnancy-induced hypertension. S Afr Med J 1992; 81: 267–70.Google ScholarPubMed
29Belfort, MA, Anthony, J, Kirshon, J. Respiratory function in severe gestational proteinuric hypertension: the effects of rapid volume expansion and subsequent vasodilatation with verapamil. Br J Obstet Gynaecol 1991; 98: 964–72.CrossRefGoogle ScholarPubMed
30Walker, JJ, Mathers, A, Bjornsson, S, Cameron, AD, Fairlie, FM. The effect of acute and chronic antihypertensive therapy on maternal and fetoplacental Doppler velocimetry. Eur J Reprod Med 1992; 43: 193–99.Google Scholar
31Carbonne, B, Jannet, D, Touboul, C, Khelifati, Y, Milliez, J. Nicardipine treatment of hypertension during pregnancy. Obstet Gynecol 1993; 81: 908–14.Google ScholarPubMed
32Parisi, VM, Salinas, J, Stockmar, E. Fetal vascular response to maternal nicardipine administration in the hypertensive ewe. Am J Obstet Gynecol 1989; 161: 1035–39.CrossRefGoogle ScholarPubMed
33Parisi, VM, Salinas, J, Stockmar, E. Placental vascular response to nicardipine in the hypertensive ewe. Am J Obstet Gynecol 1989; 161: 1039–43.CrossRefGoogle ScholarPubMed
34Belfort, MA, Saade, GR, Moise, KF, Cruz, A, Adam, K, Kramer, W et al. Nimodipine in the management of preeclampsia: maternal and fetal effects. Am J Obstet Gynecol 1994; 171: 417–24.CrossRefGoogle ScholarPubMed
35Moretti, MM, Fairlie, FM, Akl, SA, Khoury, AD, Sibai, BM. The effect of nifedipine therapy on fetal and placental Doppler waveforms in preeclampsia remote from term. Am J Obstet Gynecol 1990; 163: 1844–48.CrossRefGoogle Scholar
36Sibai, BM, Barton, JR, Akl, S, Sarinoglu, C, Mercer, BM. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol 1992; 167: 879–84.CrossRefGoogle ScholarPubMed
37Wide-Swensson, DH, Ingemarsson, I, Lunell, N-O, Forman, A, Skaaja, K, Lindberg, B. et al. Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy; a randomized placebo-controlled study. Am J Obstet Gynecol 1995; 173: 872–78.CrossRefGoogle Scholar
38Lewis, LK, Hinshaw, DB, Will, AD, Hasso, AN, Thompson, JR. CT and angiographie correlation of severe neurological disease in toxaemia of pregnancy. Neuroradiology 1988; 30: 59–64.CrossRefGoogle Scholar
39Horn, EH, Filshie, M, Kerslake, RW, Jaspan, T, Worthington, BS, Rubin, PC. Widespread cerebral ischaemia treated with nimodipine in a patient with eclampsia. Br Med J 1990; 301: 794.CrossRefGoogle Scholar
40Belfort, MA, Carpenter, RJ. Jr, Kirshon, B, Saade, GR, Moise, KJ. The use of nimodipine in a patient with eclampsia: color flow Doppler demonstration of retinal artery relaxation. Am J Obstet Gynecol 1993; 169: 204–206.CrossRefGoogle Scholar
41Hann, P, Boatwright, C, Ardlie, NG. Effect of calcium entry blocking agent nifedipine on activation of human platelets and comparison with verapamil. Thromb Haemost 1983; 50: 513–17.Google Scholar
42Li, J, Wang, Z. Effects of nimodipine on platelet aggregation and the activity of enzymes in arachidonic acid metabolism. Proc Chin Acad Med Sci Peking Union Med Coll 1990; 5: 47–50.Google ScholarPubMed
43Tschope, D, Kaufmann, L, Roesen, P, Ohlrogge, R, Gries, FA. Influence of a single dose of nitrendipine in whole blood platelet activity in healthy subjects. J Cardiovasc Pharmacol 1988; 12(Suppl 4): S167–69.CrossRefGoogle ScholarPubMed
44Yamada, Y, Furai, H, Furumichi, T, Suzuki, T, Yamauchi, K, Yokota, M et al. Inhibitory effects of endothelial cells and calcium channel blockers on platelet aggregation. Jpn Heart J 1990; 31: 201–15.CrossRefGoogle ScholarPubMed
45Glusa, E, Bevan, J, Heptinstall, S. Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation. Thrombosis Res 1989; 55: 239–45.CrossRefGoogle ScholarPubMed
46Sengelov, H, Winther, K. Effect of felodipine, a new calcium channel antagonist, on platelet function and fibrinolytic activity at rest and after exercise. Eur J Clin Pharmacol 1989; 37: 453–57.CrossRefGoogle ScholarPubMed
47Gleerup, G, Winther, K. Differential effects of nonspecific beta-blockade and calcium antagonism on blood-clotting mechanisms. Am J Med 1989; 86: 128–29.CrossRefGoogle ScholarPubMed
48Weiss, K, Itscha, P, O'Grady, J, Sinzinger, H. Isradipine: a potent calcium blocker with beneficial effects on platelet function and vascular prostacyclin production. Thromb Res 1989; 54: 311–17.CrossRefGoogle ScholarPubMed
49Francis, JL, Roath, OS, Challenor, VF, Waller, DG. The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon. Br J Clin Pharmacol 1988; 25: 751–54.CrossRefGoogle ScholarPubMed
50Rostagno, C, Prisco, D, Panicela, R, Costanzo, B, Poggesi, L, Boddi, M et al. Effects of calcium channel blockers on platelet aggregation and thromboxane A2 formation: an in vivo double-blind randomized study. Thromb Res 1990; 59: 531–39.CrossRefGoogle Scholar
51Feinberg, WM, Bruck, DC. Effect of oral nimodipine on platelet function. Stroke 1993; 24: 10–13.CrossRefGoogle ScholarPubMed
52Rubin, PC, Butters, L, McCabe, R. Nifedipine and platelets in preeclampsia. Am J Hypertens 1988; 1: 175–77.CrossRefGoogle ScholarPubMed